To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PTC Therapeutics (NasdaqGS:PTCT) Q3 2025 Earnings Call November 04, 2025 04:30 PM ET Speaker3Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics' third quarter 2025 earnings conference call. All participants are in listen-only mode. After the presentation, there will be a Q&A session. Today's call is being recorded. I would now like to turn the call over to Ellen Cavaleri, Head of Investor Relations. Please go ahead.Speaker5Good afternoon, and thank you for joining us to discuss PTC ...

Accessibility StatementSkip Navigation WARREN, N.J., Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025. Key Corporate Updates Key Clinical and Regulatory Updates Third Quarter 2025 Financial Highlights PTC Full-Year 2025 Financial Guidance For the full year 2025, PTC anticipates: Total revenue of $750 to $800 million, which includes in-line products and royalty revenue from Evrysdi.  ...

PTC Therapeutics November 2025 Pam and Kelsey living with PKU This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory subm ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy. On October 20, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on PTC Therapeutics, Inc. (NASDAQ:PTCT), lifting the price target on the stock to $87 from $76. PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential The analyst cited the solid initial demand for Sephience, which is the company’s newly approved treatment. A notable inter ...

公司业务定位 - 全球生物制药公司专注于高未满足医疗需求疗法的发现、开发和商业化 [1] 核心产品进展 - 旗舰产品Sephience获美国和欧洲批准用于治疗儿童及成人PKU患者 [1] - 该产品将成为公司未来增长的基础性产品 [1] 财务资源状况 - 第二季度末资产负债表现金余额超过19亿美元 [1] - 现金储备可支撑公司实现近期现金流盈亏平衡 [2] - 具备业务拓展资金实力以补充商业和研发产品组合 [2] 战略发展态势 - 过去1-2年重点推进公司转型并为未来建设基础 [1] - 当前进入以基础产品驱动的新增长阶段 [2] - 产品具备强劲的大规模收入潜力 [2]

公司战略转型 - 公司在过去18个月至2年内进行了重大转型 以摆脱遗留挑战并为未来成功定位 [1][3] - 公司转型努力目前已取得成果 进入新的发展阶段 [3] 核心产品进展 - 公司核心产品Sephience近期获得全球批准 包括美国和欧洲市场 [3] - Sephience被视为重大的商业机会 能使公司在近期实现现金流盈亏平衡并持续增长 [3] 财务状况 - 公司第二季度末持有超过19亿美元现金 [4] - 充足的资本不仅支持公司达到现金流盈亏平衡 也足以执行所有商业和研发优先事项 [4]